AAAAAA

   
Results: 1-7 |
Results: 7
Feasibility and safety of moderate hypothermia after massive hemispheric infarction
Authors: Schwab, S Georgiadis, D Berrouschot, J Schellinger, PD Graffagnino, C Mayer, SA
Citation: S. Schwab et al., Feasibility and safety of moderate hypothermia after massive hemispheric infarction, STROKE, 32(9), 2001, pp. 2033-2035
Abciximab in acute ischemic stroke - A randomized, double-blind, placebo-controlled, dose-escalation study
Authors: Adams, HP Bogousslavsky, J Barnathan, E Brott, T Fisher, M Furlan, AJ Graffagnino, C Kappelle, J Kothari, R Leclerc, JR Moulin, T Polzer, J Torner, J Worley, S Haley, CE Day, JH Levine, SR Thompson, JLP Sherman, DG Sane, DC Maley, JE Grimsman, KJ Maeder, M Clarke, WR Anderson, K Cook, R FitzPatrick, S Peeters, A Cras, P Blecic, S Laloux, P Chatel, M Mahagne, H Moulin, T Hacke, W Diener, HC Bogousslavsky, J Maeder, M Kappelle, LJ Vermulen, M Kwa, VIH Franke, CL Jacoby, M Libman, R Hsu, C Kothari, R Raps, EC Kasner, SE Scott, P Karanjia, P Heiselman, D Graffagnino, C Graham, G Akins, PT Brott, T Meschia, J Furlan, AJ Gordon, D Jackson, CM Starkman, S Wityk, R Worley, S Adams, HP Belden, JR Dashe, J Fisher, M Gomez, C Hwang, TL Jichici, D Thompson, D Adams, HP Barnathan, E Bogousslavsky, J Brott, T Fisher, M Furlan, AJ Hacke, W Kappelle, J Kothari, R Leclerc, JR Moulin, T Polzer, J Scott, P Torner, J
Citation: Hp. Adams et al., Abciximab in acute ischemic stroke - A randomized, double-blind, placebo-controlled, dose-escalation study, STROKE, 31(3), 2000, pp. 601-609
Dose-finding, safety, and tolerability study of an oral platelet glycoprotein IIb/IIIa inhibitor, lotrafiban, in patients with coronary or cerebral atherosclerotic disease
Authors: Harrington, RA Armstrong, PW Graffagnino, C Van de Werf, F Kereiakes, DJ Sigmon, KN Card, T Joseph, DM Samuels, R Granett, J Chan, R Califf, RM Topol, EJ
Citation: Ra. Harrington et al., Dose-finding, safety, and tolerability study of an oral platelet glycoprotein IIb/IIIa inhibitor, lotrafiban, in patients with coronary or cerebral atherosclerotic disease, CIRCULATION, 102(7), 2000, pp. 728-735
Design of the blockade of the glycoprotein IIb/IIIa receptor to avoid vascular occlusion (BRAVO) trial
Authors: Topol, EJ Easton, JD Amarenco, P Califf, R Harrington, R Graffagnino, C Davis, S Diener, HC Ferguson, J Fitzgerald, D Shuaib, A Koudstaal, PJ Theroux, P Van de Werf, F Willerson, JT Chan, R Samuels, R Ilson, B Granett, J
Citation: Ej. Topol et al., Design of the blockade of the glycoprotein IIb/IIIa receptor to avoid vascular occlusion (BRAVO) trial, AM HEART J, 139(6), 2000, pp. 927-933
Stroke in patients with acute coronary syndromes - Incidence and outcomes in the platelet glycoprotein IIb/IIIa in unstable angina: Receptor suppression using integrilin therapy (PURSUIT) trial
Authors: Mahaffey, KW Harrington, RA Simoons, ML Granger, CB Graffagnino, C Alberts, MJ Laskowitz, DT Miller, JM Sloan, MA Berdan, LG MacAulay, CM Lincoff, AM Deckers, J Topol, EJ Califf, RM
Citation: Kw. Mahaffey et al., Stroke in patients with acute coronary syndromes - Incidence and outcomes in the platelet glycoprotein IIb/IIIa in unstable angina: Receptor suppression using integrilin therapy (PURSUIT) trial, CIRCULATION, 99(18), 1999, pp. 2371-2377
Progressing stroke
Authors: Graffagnino, C
Citation: C. Graffagnino, Progressing stroke, NEUROL DIS, 48, 1999, pp. 129-140
Molecular genetics of lipid metabolism
Authors: Graffagnino, C
Citation: C. Graffagnino, Molecular genetics of lipid metabolism, GENETICS OF CEREBROVASCULAR DISEASE, 1999, pp. 81-115
Risultati: 1-7 |